"We are clinical pharmacologists and drug developers with innate ability to aid in solving drug development challenges and developing straight forward strategies for successful therapies."
Scott D. Collins, Parmita Saxena, Xiao Y. Li, Yeonju Shim, Lance Ostrom, Nicholas C. Yoder, Kalli C. Catcott, Molly A. McShea, Xiuxia Sun, Sanela Bilic, William R. Tschantz, Meghan Flaherty, Keith Mansfield, Tiancen Hu, Vladimir Capka, Markus Kurz, Ivana Liric Rajlic, Anne Serdakowski London, Duc Nguyen, Rebecca Mosher, Matthew J. Meyer, Aaron Bourret, Jamal Saeh, Scott Cameron, Emma Lees and Carl U. Bialucha. Targeting cadherin-6 (CDH6) with an antibody-drug conjugate for the treatment of ovarian and renal cancer, AACR 2016
Karen Thudium, Hequn Yin, Sanela Bilic. Dose Selection for a Potent Fully Human Antagonist Monoclonal Antibody (mAb), Compound X: Strategies for Selecting a Safe and Pharmacologically Active Dose, AAPS NBC 2012
Heather Huet1, Alwin Schuller1, Jing Li1, Jennifer Johnson1, Bruno Dombrecht2, Kris Meerschaert2, Karen Cromie2, Sanela Bilic3, Sharon Li1, Andrew Garner1, Sandra Nunes1, Rajiv Chopra1, Kirk Clark1, Megan Yao1, Stephen Fawell1, David Stover1, William R. Sellers1, and Seth Ettenberg1, TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches, AACR 2012
S. Bilic, S. Kakar, S. Ettenberg, M. Daley, B. Granda, Z. Yang, B. Jaitner, D. Stoellner, H. Schran, A. Skerjanec, Beyond Immunoassays: Comparative pharmacokinetics of Monoclonal Antibodies using LCMS and ELISA, AAPS NBC 2010
Swaminathan Padmanabhan Joseph Thaddeus Beck Padmanabhan, Joseph Thaddeus Beck, Kevin R. Kelly, Nikhil C. Munshi, Andy Dzik-Jurasz, Esha Gangolli, Seth Ettenberg, Kelly Miner, Sanela Bilic, Winston Whyte, Fazal Mehdi, Lu-May Chiang, Patricia Liz Rae, Andrew Spencer, Jatin Shah, Kenneth C. Anderson, Francis J. Giles, and A. Keith Stewart, A Phase I/II Study of BHQ**), an Anti-DKK-1 Antibody, in Patients with Relapsed or Refractory Multiple Myeloma Tretaed with Anti-myeloma Therapy and Zoledronic Acid. ASH 2009.
S. Sharma1, E. G. de Vries2, J. R. Infante3, C. Oldenhuis2, L. Chiang4, S. Bilic4, M. Goldbrunner4, J. W. Scott4, H. A. Burris, III3 1 Nevada Cancer Institute, US 2 University Medical Center Groningen, NL 3 Sarah Cannon Research Institute, US 4 Novartis Pharmaceuticals, Phase I trial of LBY135, a monoclonal antibody against DR5, alone and in combination with Capecitabine in advanced solid tumors, American Sociaty of Clinical Oncology, Annual Meeting May 30 – June 3rd 2008, Chicago, IL
John C. Byrd,1 Ian W. Flinn,2 Khuda Dad Khan,3 Thomas J. Kipps,4 Lea Aukerman,5 Judith Fox,5 Sandhya Girish,5 Serge Guzy,6 Sanela Bilic, 5 Alan Solinger,6 Sherri Dort,5 Yongyu Wang,5 Deborah Hurst,5 Susan O’Brien.7 1The Ohio State Univ, Columbus, OH, 2Johns Hopkins Medical Ctr, Baltimore, MD, 3 St. Francis Cancer Res. Found, Beech Grove, IN, 4 Univ. of California San Diego, La Jolla, CA, 5Novartis Oncology, Florham Park NJ and Emeryville CA. 6XOMA Ltd, Berkeley, CA, 7M.D Anderson Cancer Ctr., Houston, TX Pharmacokinetics and Pharmacodynamics from a First-in-human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia, American Society of Hematology, Annual Meeting Dec 4-7, 2006, Orlando, FL.
William Bensinger,1 Sundar Jagannath,2 Pamela Becker,1 Kenneth Anderson,3 Edward Stadtmauer,4 Lea Aukerman,5 Judith Fox,5 Sandhya Girish,5 Sanela Bilic,5 Serge Guzy,6 Alan Solinger,6 Sherri Dort,5 Yongyu Wang,5 Deborah Hurst.5 1Fred Hutchinson Cancer Research Ctr., Seattle, WA, 2St.Vincent’s Comprehensive Cancer Ctr., New York, NY, 3 Dana-Farber Cancer Institute, Boston, MA, 4Univ. of Pennsylvania, Philadelphia, PA 5Novartis Oncology, Florham Park, NJ and Emeryville, CA, 6XOMA Ltd, Berkeley, CA. A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma
Julia Zayezdnaya Zack, Alan Forrest, Sanela Bilic, Pam Kelchlin, Patrick F. Smith. PK/PD in silico and in vitro Simulations of Linezolid (LZD) Activity against Methicillin-Resistant Staphylococcus aureus (MRSA). 14th Symposium of International Society of Anti-Infective Pharmacology in cooperation with 45th International Conference on Antimicrobial Agents and Chemotherapy, Washington D.C. October 2005. Platform Presentation.
Julia Zayezdnaya Zack, Alan Forrest, Sanela Bilic, Pam Kelchlin, Patrick F. Smith. Application of theoretical PK/PD modeling for optimization of linezolid therapy. American Society of Microbiology 45th International Conference on Antimicrobial Agents and Chemotherapy, Washington D.C. December 2005
W Schröder, S Abadie, P O Witteveen, M Campone, P Viens, T Jalava, E Masson, S Bilic, A Chlistalla, A du Bois, Antiangiogenesis- A New Treatment Modality for Ovarian Cancer Patients. 13th International The European Cancer Conference, October 30 – November 3, 2005. Paris, France.
W Schröder, S Abadie, P O Witteveen, M Campone, P Viens, T Jalava, E Masson, S Bilic, A Chlistalla, A du Bois, Antiangiogenesis- A New Treatment Modality for Ovarian Cancer Patients. 14th International European Society of Gynaecological Oncology, September 25-29th,2005. Istanbul, Turkey.
Pierre Major, James Berenson, Regina Swift, Robert Vescio, Christina Ravera, Sanela Bilic, Sonia Gauron, Jannick Denouel, Horst Schran, The Effect of Zoledronic Acid (Zol) Dose and Infusion Rate on Pharmacokinetics (PK), Pharmacodynamics (PD), and Renal Function in Patients (pts) With Multiple Myeloma (MM) or Prostate Cancer (PC) and Bone Metastases. American Society of Clinical Oncology, May 13-17, 2005. Orlando, Fl.
S Bilic, AB Ogundele, CM Rubino, PF Smith, Clinical Evaluation and Comparison of Erythropoietic Growth Factors (EGF) for Chemotherapy induced Anemia American Society of Clinical Pharmacology and Therapeutics, Annual Meeting March 2-5, 2005, Orlando, Fl.
Olanrewaju O Okusanya, Alan Forrest, Sanela Bilic, Sue Rosenkranz, Michael F Para, Elizabeth Adams, Kevin E Yaresheski, Richard C Reichman, Gene D Morse, AACTG A5043 Protocol Team. Compartmental Analysis of Amprenavir Pharmacokinetics including Secondary Peaks. American College of Clinical Pharmacy Annual Meeting. Dallas, TX, October 23-5, 2004.
S Bilic, BM Booker, P Kelchlin, A Forrest, PF Smith. Development of a Pharmacokinetic/Pharmacodynamic Model To Characterize the In Vitro Activity and Dose-Response Relationships of Daptomycin and Linezolid against Vancomycin Resistant Enterococci Using Subpopulation Analysis. American College of Clinical Pharmacy Annual Meeting. Dallas, TX, October 23-5, 2004. Poster Encore
James Berenson, Pierre Major, Regina Swift, Christina Ravera, Sanela Bilic, Sonia Gauron, Jannick Denouel, Horst Schran. The Effect of Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics, Pharmacodynamics, and Renal Function in Patients With Multiple Myeloma. American Society of Hematology, Annual Meeting Dec 4-7, 2004. San Diego, CA.
BM Booker, PF Smith, A Forrest, P Kelchlin, S Bajic, S. M. Bhavnani, P. G. Ambrose. Pharmacodynamics of Cefprozil against Haemophilus influenzae in an in vitro Infection Model. 44th International Conference of on Antimicrobial Agents and Chemotherapy, Washington D.C., October 2004.
S Bajic, BM Booker, P Kelchlin, A Forrest, PF Smith. Development of a Pharmacokinetic/Pharmacodynamic Model To Characterize the In Vitro Activity and Dose-Response Relationships of Daptomycin and Linezolid against Vancomycin Resistant Enterococci Using Subpopulation Analysis. 14th European Congress of Clinical Microbiology and Infectious Diseases. May 1-4, Prague, Czech Republic 2004.
Bajic S, Booker BM, Kelchlin P, Smith PF. In Vitro Activity of Linezolid, Quinupristin/Dalfopristin and Daptomycin Against Multi-Drug Resistant Gram Positive Bacteria. American College of Clinical Pharmacy / European Society of Clinical Pharmacist – 2nd International Congress of Clinical Pharmacy, April 27-30, Paris, France 2004.
Patrick F. Smith, Brent M. Booker, Sanela Bajic. A novel in vitro model for experimental therapeutic and pharmacokinetic/pharmacodynamic studies of antineoplastic drugs. [abstract 2127] 95th Annual meeting of American Association for Cancer Research, March 27-31, Orlando, Florida 2004.